146 related articles for article (PubMed ID: 37003194)
21. Relationship between choice of opioid agonist therapy and distance from patients' residences in Taiwan, 2012-2014.
Wei LC; Chan HY
Am J Drug Alcohol Abuse; 2021 Sep; 47(5):590-598. PubMed ID: 34402338
[TBL] [Abstract][Full Text] [Related]
22. [New slow-release buprenorphine formulations for optimization of opioid substitution].
Soyka M; Pogarell O
Nervenarzt; 2019 Sep; 90(9):932-937. PubMed ID: 31399813
[TBL] [Abstract][Full Text] [Related]
23. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
[TBL] [Abstract][Full Text] [Related]
24. Does the advent of depot therapy represent a step change in our understanding of opioid use disorder and its treatment?
Roberts E; Humphreys K
Drug Alcohol Rev; 2024 Jan; 43(1):261-264. PubMed ID: 37525510
[TBL] [Abstract][Full Text] [Related]
25. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.
Larance B; Degenhardt L; Grebely J; Nielsen S; Bruno R; Dietze P; Lancaster K; Larney S; Santo T; Shanahan M; Memedovic S; Ali R; Farrell M
Addiction; 2020 Jul; 115(7):1295-1305. PubMed ID: 31860767
[TBL] [Abstract][Full Text] [Related]
26. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
[TBL] [Abstract][Full Text] [Related]
27. "The Doctor Says You Cannot Have [Buprenorphine]" Autonomy and Use of Prescribed or Non-Prescribed Buprenorphine.
Hayes BT; Jakubowski A; Fitzsimmons C; Garcia B; Ramirez F; Fox AD
Subst Use Misuse; 2021; 56(8):1137-1143. PubMed ID: 33939937
[TBL] [Abstract][Full Text] [Related]
28. Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings.
Dunlop AJ; White B; Roberts J; Cretikos M; Attalla D; Ling R; Searles A; Mackson J; Doyle MF; McEntyre E; Attia J; Oldmeadow C; Howard MV; Murrell T; Haber PS; Lintzeris N
Addiction; 2022 Feb; 117(2):382-391. PubMed ID: 34184798
[TBL] [Abstract][Full Text] [Related]
29. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
[TBL] [Abstract][Full Text] [Related]
30. Transitioning off methadone: A qualitative study exploring why patients discontinue methadone treatment for opioid use disorder.
Thakrar AP; Pytell JD; Stoller KB; Walters V; Weiss RD; Chander G
J Subst Use Addict Treat; 2023 Jul; 150():209055. PubMed ID: 37088398
[TBL] [Abstract][Full Text] [Related]
31. Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
Soyka M; Groß G
Am J Drug Alcohol Abuse; 2021 Sep; 47(5):599-604. PubMed ID: 34407703
[TBL] [Abstract][Full Text] [Related]
32. Medication Treatment of Opioid Use Disorder.
Bell J; Strang J
Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089
[TBL] [Abstract][Full Text] [Related]
33. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
[TBL] [Abstract][Full Text] [Related]
34. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
[TBL] [Abstract][Full Text] [Related]
35. How do patients feel during the first 72 h after initiating long-acting injectable buprenorphine? An embodied qualitative analysis.
Neale J; Parkin S; Strang J
Addiction; 2023 Jul; 118(7):1329-1339. PubMed ID: 36808168
[TBL] [Abstract][Full Text] [Related]
36. Flexible delivery of opioid agonist treatment during COVID-19 in Norway: qualitative and quantitative findings from an online survey of provider experiences.
McDonald R; Bech AB; Clausen T
BMC Health Serv Res; 2023 Sep; 23(1):965. PubMed ID: 37679751
[TBL] [Abstract][Full Text] [Related]
37. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
[TBL] [Abstract][Full Text] [Related]
38. "I'm a Survivor": Perceptions of Chronic Disease and Survivorship Among Individuals in Long-Term Remission from Opioid Use Disorder.
Pytell JD; Sklar MD; Carrese J; Rastegar DA; Gunn C; Chander G
J Gen Intern Med; 2022 Feb; 37(3):593-600. PubMed ID: 34027611
[TBL] [Abstract][Full Text] [Related]
39. Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey: Findings from a longitudinal qualitative study.
Parkin S; Neale J; Strang J
Int J Drug Policy; 2023 Dec; 122():104221. PubMed ID: 37865052
[TBL] [Abstract][Full Text] [Related]
40. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
